The University of Chicago Header Logo

Connection

John Fung to Tacrolimus

Back to Details
This is a "connection" page, showing publications John Fung has written about Tacrolimus.
John Fung
Connection Strength
9.745
Tacrolimus
  1. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. Transplantation. 2017 Feb; 101(2):341-349.
    View in: PubMed
    Score: 0.529
  2. Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl. 2008 Jan; 14(1):46-52.
    View in: PubMed
    Score: 0.282
  3. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation. 2005 Sep 27; 80(6):859-64.
    View in: PubMed
    Score: 0.241
  4. Tacrolimus and transplantation: a decade in review. Transplantation. 2004 May 15; 77(9 Suppl):S41-3.
    View in: PubMed
    Score: 0.219
  5. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation. 2004 Mar 27; 77(6):897-902.
    View in: PubMed
    Score: 0.217
  6. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003 Sep 15; 76(5):827-32.
    View in: PubMed
    Score: 0.209
  7. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003 Sep; 9(9):954-60.
    View in: PubMed
    Score: 0.209
  8. Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation. Exp Clin Transplant. 2003 Jun; 1(1):48-55.
    View in: PubMed
    Score: 0.205
  9. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003 May 03; 361(9368):1502-10.
    View in: PubMed
    Score: 0.204
  10. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 2002 Sep; 8(9):841-5.
    View in: PubMed
    Score: 0.195
  11. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc. 2002 Aug; 34(5):1540-1.
    View in: PubMed
    Score: 0.194
  12. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001 Sep 27; 72(6):1091-7.
    View in: PubMed
    Score: 0.183
  13. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 2001 Jul; 7(7):623-30.
    View in: PubMed
    Score: 0.180
  14. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation. 2001 Apr 27; 71(8):1102-6.
    View in: PubMed
    Score: 0.177
  15. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001 Mar; 41(3):268-76.
    View in: PubMed
    Score: 0.175
  16. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc. 2001 Feb-Mar; 33(1-2):1342-4.
    View in: PubMed
    Score: 0.174
  17. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc. 2000 May; 32(3):663-4.
    View in: PubMed
    Score: 0.166
  18. Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord. 1999 Jun; 9(2):101-3.
    View in: PubMed
    Score: 0.155
  19. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg. 1999 Mar; 5(2):144-50.
    View in: PubMed
    Score: 0.153
  20. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27; 66(10):1395-8.
    View in: PubMed
    Score: 0.150
  21. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg. 1998 Nov; 4(6):448-54.
    View in: PubMed
    Score: 0.149
  22. Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis. 1998 Jun; 31(6 Suppl 1):S7-14.
    View in: PubMed
    Score: 0.145
  23. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc. 1998 Jun; 30(4):1403-4.
    View in: PubMed
    Score: 0.145
  24. Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation. 1998 Apr 27; 65(8):1140.
    View in: PubMed
    Score: 0.144
  25. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg. 1996 Aug; 183(2):117-25.
    View in: PubMed
    Score: 0.128
  26. FK506 in solid organ transplantation. Ther Drug Monit. 1995 Dec; 17(6):592-5.
    View in: PubMed
    Score: 0.122
  27. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99(7):1455-62.
    View in: PubMed
    Score: 0.118
  28. FK 506 in solid organ transplantation. Transplant Proc. 1994 Oct; 26(5):3017-20.
    View in: PubMed
    Score: 0.112
  29. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc. 1994 Jun; 26(3):1211.
    View in: PubMed
    Score: 0.110
  30. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation. 1994 Mar 27; 57(6):860-5.
    View in: PubMed
    Score: 0.108
  31. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
    View in: PubMed
    Score: 0.107
  32. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity. 1994; 19(2):89-98.
    View in: PubMed
    Score: 0.107
  33. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. Transplant Proc. 1991 Dec; 23(6):3026-8.
    View in: PubMed
    Score: 0.092
  34. Adverse effects associated with the use of FK 506. Transplant Proc. 1991 Dec; 23(6):3105-8.
    View in: PubMed
    Score: 0.092
  35. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transplant Proc. 1991 Dec; 23(6):3234-5.
    View in: PubMed
    Score: 0.092
  36. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. Transplant Proc. 1991 Dec; 23(6):3238-9.
    View in: PubMed
    Score: 0.092
  37. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation. 2006 Dec 27; 82(12):1621-4.
    View in: PubMed
    Score: 0.066
  38. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation. 2006 Dec 27; 82(12):1649-52.
    View in: PubMed
    Score: 0.066
  39. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation. 2004 Dec 15; 78(11):1683-8.
    View in: PubMed
    Score: 0.057
  40. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004 Oct 15; 78(7):966-71.
    View in: PubMed
    Score: 0.056
  41. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg. 2003 Oct; 238(4):520-5; discussion 525-7.
    View in: PubMed
    Score: 0.052
  42. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation. 2003 Apr 15; 75(7):1020-5.
    View in: PubMed
    Score: 0.051
  43. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc. 2002 Aug; 34(5):1651-2.
    View in: PubMed
    Score: 0.048
  44. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc. 2002 Aug; 34(5):1968-9.
    View in: PubMed
    Score: 0.048
  45. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002 Jan; 8(1):40-6.
    View in: PubMed
    Score: 0.046
  46. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001 Oct; 5(5):359-64.
    View in: PubMed
    Score: 0.046
  47. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 2001 Sep 15; 72(5):851-5.
    View in: PubMed
    Score: 0.046
  48. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001 Aug; 23(4):354-62.
    View in: PubMed
    Score: 0.045
  49. Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 05 01; 106(5):997-1003.
    View in: PubMed
    Score: 0.045
  50. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation. 2001 Jan 27; 71(2):267-71.
    View in: PubMed
    Score: 0.044
  51. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. Transplant Proc. 2000 Dec; 32(8):2710-2.
    View in: PubMed
    Score: 0.043
  52. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 2000 Sep 15; 70(5):760-4.
    View in: PubMed
    Score: 0.042
  53. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000 Jun 15; 69(11):2330-6.
    View in: PubMed
    Score: 0.042
  54. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000 Jan 27; 69(2):265-71.
    View in: PubMed
    Score: 0.041
  55. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27; 68(12):1851-4.
    View in: PubMed
    Score: 0.040
  56. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1999 Sep 15; 68(5):650-5.
    View in: PubMed
    Score: 0.040
  57. Posttransplant diabetes in pediatric recipients on tacrolimus. Transplantation. 1999 Mar 15; 67(5):771.
    View in: PubMed
    Score: 0.038
  58. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999 Feb 15; 67(3):411-5.
    View in: PubMed
    Score: 0.038
  59. Immunosuppressive therapy. Surg Clin North Am. 1999 Feb; 79(1):59-76.
    View in: PubMed
    Score: 0.038
  60. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc. 1999 Feb-Mar; 31(1-2):646-7.
    View in: PubMed
    Score: 0.038
  61. Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc. 1999 Feb-Mar; 31(1-2):700-1.
    View in: PubMed
    Score: 0.038
  62. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999 Feb-Mar; 31(1-2):1134.
    View in: PubMed
    Score: 0.038
  63. Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation. 1999 Jan 27; 67(2):266-72.
    View in: PubMed
    Score: 0.038
  64. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation. 1999 Jan 27; 67(2):299-303.
    View in: PubMed
    Score: 0.038
  65. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol. 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6.
    View in: PubMed
    Score: 0.038
  66. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998 Oct 27; 66(8):1047-52.
    View in: PubMed
    Score: 0.037
  67. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. Transplant Proc. 1998 Jun; 30(4):1091-2.
    View in: PubMed
    Score: 0.036
  68. Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc. 1998 Jun; 30(4):1257-60.
    View in: PubMed
    Score: 0.036
  69. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1375-7.
    View in: PubMed
    Score: 0.036
  70. Alopecia as a consequence of tacrolimus therapy. Transplantation. 1998 May 15; 65(9):1284.
    View in: PubMed
    Score: 0.036
  71. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transplant Proc. 1998 Mar; 30(2):521.
    View in: PubMed
    Score: 0.036
  72. Outcome of kidney transplantation in African-Americans using tacrolimus. Transplant Proc. 1997 Dec; 29(8):3731-2.
    View in: PubMed
    Score: 0.035
  73. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997 Sep; 29(6):2737-8.
    View in: PubMed
    Score: 0.034
  74. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997 Aug 27; 64(4):559-65.
    View in: PubMed
    Score: 0.034
  75. Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):306.
    View in: PubMed
    Score: 0.033
  76. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):310.
    View in: PubMed
    Score: 0.033
  77. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc. 1997 Feb-Mar; 29(1-2):532-3.
    View in: PubMed
    Score: 0.033
  78. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1081-2.
    View in: PubMed
    Score: 0.033
  79. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation. 1997 Jan 27; 63(2):223-8.
    View in: PubMed
    Score: 0.033
  80. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation. 1996 Nov 15; 62(9):1242-6.
    View in: PubMed
    Score: 0.033
  81. Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc. 1996 Aug; 28(4):2119-20.
    View in: PubMed
    Score: 0.032
  82. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation. 1996 Jun 27; 61(12):1730-5.
    View in: PubMed
    Score: 0.032
  83. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. Transplant Proc. 1996 Apr; 28(2):736-7.
    View in: PubMed
    Score: 0.031
  84. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995 Nov 18; 346(8986):1346-50.
    View in: PubMed
    Score: 0.030
  85. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. Transplantation. 1995 Sep 15; 60(5):512-4.
    View in: PubMed
    Score: 0.030
  86. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation. 1995 Feb 27; 59(4):485-90.
    View in: PubMed
    Score: 0.029
  87. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc. 1995 Feb; 27(1):1099-104.
    View in: PubMed
    Score: 0.029
  88. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc. 1995 Feb; 27(1):277.
    View in: PubMed
    Score: 0.029
  89. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc. 1995 Feb; 27(1):814-7.
    View in: PubMed
    Score: 0.029
  90. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg. 1994 Sep; 220(3):297-308; discussion 308-9.
    View in: PubMed
    Score: 0.028
  91. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. Transplant Proc. 1994 Jun; 26(3):1208.
    View in: PubMed
    Score: 0.027
  92. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med. 1993 Oct 01; 119(7 Pt 1):595-8.
    View in: PubMed
    Score: 0.026
  93. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2433-4.
    View in: PubMed
    Score: 0.026
  94. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2435.
    View in: PubMed
    Score: 0.026
  95. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc. 1993 Jun; 25(3):2381-5.
    View in: PubMed
    Score: 0.026
  96. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. Bone Marrow Transplant. 1993 Jun; 11(6):502.
    View in: PubMed
    Score: 0.026
  97. FK 506 interaction with danazol. Lancet. 1993 May 22; 341(8856):1344-5.
    View in: PubMed
    Score: 0.026
  98. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation. 1993 Mar; 55(3):659-61.
    View in: PubMed
    Score: 0.025
  99. Two-year experience with FK 506 in pediatric patients. Transplant Proc. 1993 Feb; 25(1 Pt 1):619-21.
    View in: PubMed
    Score: 0.025
  100. Long-term survival of heart and liver xenografts with splenectomy and FK 506. Transplant Proc. 1993 Feb; 25(1 Pt 1):647-8.
    View in: PubMed
    Score: 0.025
  101. Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc. 1993 Feb; 25(1 Pt 1):669-72.
    View in: PubMed
    Score: 0.025
  102. Intestinal transplantation in humans under FK 506. Transplant Proc. 1993 Feb; 25(1 Pt 2):1198-9.
    View in: PubMed
    Score: 0.025
  103. Intestinal transplantation in composite visceral grafts or alone. Ann Surg. 1992 Sep; 216(3):223-33; discussion 233-4.
    View in: PubMed
    Score: 0.024
  104. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. Transplant Proc. 1992 Aug; 24(4):1403-5.
    View in: PubMed
    Score: 0.024
  105. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992 Jun; 128(6):781-5.
    View in: PubMed
    Score: 0.024
  106. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. Transplant Proc. 1992 Jun; 24(3):1042.
    View in: PubMed
    Score: 0.024
  107. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992 May; 53(5):1056-62.
    View in: PubMed
    Score: 0.024
  108. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. Am J Hosp Pharm. 1992 Jan; 49(1):119-22.
    View in: PubMed
    Score: 0.023
  109. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc. 1991 Dec; 23(6):2771-4.
    View in: PubMed
    Score: 0.023
  110. Interaction between FK 506 and cyclosporine in dogs. Transplant Proc. 1991 Dec; 23(6):2797-9.
    View in: PubMed
    Score: 0.023
  111. The pharmacodynamics of pentobarbital following FK 506 therapy. Transplant Proc. 1991 Dec; 23(6):2800-1.
    View in: PubMed
    Score: 0.023
  112. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc. 1991 Dec; 23(6):2873-4.
    View in: PubMed
    Score: 0.023
  113. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc. 1991 Dec; 23(6):2957-8.
    View in: PubMed
    Score: 0.023
  114. FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc. 1991 Dec; 23(6):3010-5.
    View in: PubMed
    Score: 0.023
  115. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc. 1991 Dec; 23(6):3016-8.
    View in: PubMed
    Score: 0.023
  116. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc. 1991 Dec; 23(6):3023-5.
    View in: PubMed
    Score: 0.023
  117. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3035-7.
    View in: PubMed
    Score: 0.023
  118. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3044-6.
    View in: PubMed
    Score: 0.023
  119. Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3093-5.
    View in: PubMed
    Score: 0.023
  120. Changes in renal function after liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3143-5.
    View in: PubMed
    Score: 0.023
  121. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc. 1991 Dec; 23(6):3148-9.
    View in: PubMed
    Score: 0.023
  122. Neurologic complications of FK 506. Transplant Proc. 1991 Dec; 23(6):3175-8.
    View in: PubMed
    Score: 0.023
  123. Human islet allotransplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3207.
    View in: PubMed
    Score: 0.023
  124. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3225-7.
    View in: PubMed
    Score: 0.023
  125. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3232-3.
    View in: PubMed
    Score: 0.023
  126. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3269-71.
    View in: PubMed
    Score: 0.023
  127. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc. 1991 Dec; 23(6):3322-4.
    View in: PubMed
    Score: 0.023
  128. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant Proc. 1991 Dec; 23(6):3325-7.
    View in: PubMed
    Score: 0.023
  129. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991 Dec; 23(6):3328-9.
    View in: PubMed
    Score: 0.023
  130. Treatment of Cogan's syndrome with FK 506: a case report. Transplant Proc. 1991 Dec; 23(6):3347.
    View in: PubMed
    Score: 0.023
  131. [Clinical experience with FK 506]. Presse Med. 1991 Nov 27; 20(40):1967-73.
    View in: PubMed
    Score: 0.023
  132. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation. 1991 Oct; 52(4):590-4.
    View in: PubMed
    Score: 0.023
  133. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
    View in: PubMed
    Score: 0.022
  134. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc. 1990 Feb; 22(1):52-6.
    View in: PubMed
    Score: 0.020
  135. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22(1):6-12.
    View in: PubMed
    Score: 0.020
  136. Overview of FK506 in transplantation. Clin Transpl. 1990; 115-21.
    View in: PubMed
    Score: 0.020
  137. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl. 2005 Nov; 11(11):1343-52.
    View in: PubMed
    Score: 0.015
  138. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005 Apr; 200(4):505-15; quiz A59-61.
    View in: PubMed
    Score: 0.015
  139. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005 Mar; 37(2):923-6.
    View in: PubMed
    Score: 0.014
  140. Synergistic effect of cold and warm ischemia time on postoperative graft outcome in human liver transplantation. Hepatogastroenterology. 2004 Sep-Oct; 51(59):1413-6.
    View in: PubMed
    Score: 0.014
  141. Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl. 2004 Feb; 10(2):253-63.
    View in: PubMed
    Score: 0.013
  142. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003 Apr; 17(2):77-88.
    View in: PubMed
    Score: 0.013
  143. Hamster-to-rat bone marrow xenotransplantation and humoral graft vs. host disease. Xenotransplantation. 2001 Aug; 8(3):213-21.
    View in: PubMed
    Score: 0.011
  144. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol. 2001 Apr; 158(4):1379-90.
    View in: PubMed
    Score: 0.011
  145. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 2001 Feb-Mar; 33(1-2):1235-6.
    View in: PubMed
    Score: 0.011
  146. The long-term efficacy of multivisceral transplantation. Transplant Proc. 2000 Sep; 32(6):1219-20.
    View in: PubMed
    Score: 0.011
  147. Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. Transplant Proc. 2000 Aug; 32(5):1036-7.
    View in: PubMed
    Score: 0.011
  148. Loss of serum bicarbonate after discordant liver xenotransplantation. Transplant Proc. 2000 Aug; 32(5):1110.
    View in: PubMed
    Score: 0.011
  149. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg. 1999 Mar; 5(2):101-6.
    View in: PubMed
    Score: 0.010
  150. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
    View in: PubMed
    Score: 0.009
  151. Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl. 1999; 217-21.
    View in: PubMed
    Score: 0.009
  152. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May; 186(5):512-25; discussion 525-7.
    View in: PubMed
    Score: 0.009
  153. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998 Feb 27; 65(4):499-504.
    View in: PubMed
    Score: 0.009
  154. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997 Jul 27; 64(2):252-7.
    View in: PubMed
    Score: 0.009
  155. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997 Jul-Aug; 44(16):1172-81.
    View in: PubMed
    Score: 0.009
  156. Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. Transplant Proc. 1997 Feb-Mar; 29(1-2):454-5.
    View in: PubMed
    Score: 0.008
  157. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. Transplant Proc. 1997 Feb-Mar; 29(1-2):700.
    View in: PubMed
    Score: 0.008
  158. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997 Jan 27; 63(2):243-9.
    View in: PubMed
    Score: 0.008
  159. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc. 1996 Oct; 28(5):2959-65.
    View in: PubMed
    Score: 0.008
  160. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):733-4.
    View in: PubMed
    Score: 0.008
  161. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. Transplant Proc. 1996 Apr; 28(2):735.
    View in: PubMed
    Score: 0.008
  162. Small bowel transplantation: current progress and clinical application. Hepatogastroenterology. 1996 Mar-Apr; 43(8):363-76.
    View in: PubMed
    Score: 0.008
  163. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest. 1996 Jan 01; 97(1):217-25.
    View in: PubMed
    Score: 0.008
  164. Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc. 1995 Feb; 27(1):300-2.
    View in: PubMed
    Score: 0.007
  165. Three years clinical experience with intestinal transplantation. J Am Coll Surg. 1994 Oct; 179(4):385-400.
    View in: PubMed
    Score: 0.007
  166. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Transplant Proc. 1994 Jun; 26(3):1255.
    View in: PubMed
    Score: 0.007
  167. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc. 1993 Dec; 25(6):3337-44.
    View in: PubMed
    Score: 0.007
  168. Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation. 1993 Aug; 56(2):482-4.
    View in: PubMed
    Score: 0.006
  169. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol. 1993 Jul; 143(1):85-98.
    View in: PubMed
    Score: 0.006
  170. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc. 1993 Feb; 25(1 Pt 1):414-5.
    View in: PubMed
    Score: 0.006
  171. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc. 1993 Feb; 25(1 Pt 1):781-3.
    View in: PubMed
    Score: 0.006
  172. Nutritional management of intestinal transplant recipients. Transplant Proc. 1993 Feb; 25(1 Pt 2):1200-1.
    View in: PubMed
    Score: 0.006
  173. Management of intestinal transplantation in humans. Transplant Proc. 1992 Jun; 24(3):1243-4.
    View in: PubMed
    Score: 0.006
  174. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc. 1991 Dec; 23(6):3021-2.
    View in: PubMed
    Score: 0.006
  175. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991 Aug; 110(2):357-63; discussion 363-4.
    View in: PubMed
    Score: 0.006
  176. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991 Jul; 52(1):71-7.
    View in: PubMed
    Score: 0.006
  177. Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation. 1991 Apr; 51(4):913-5.
    View in: PubMed
    Score: 0.006
  178. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc. 1991 Feb; 23(1 Pt 2):1108-10.
    View in: PubMed
    Score: 0.005
  179. Liver transplantation under cyclosporine: a decade of experience. Transplant Proc. 1991 Feb; 23(1 Pt 2):1393-6.
    View in: PubMed
    Score: 0.005
  180. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991 Feb; 23(1 Pt 2):1397-402.
    View in: PubMed
    Score: 0.005
  181. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc. 1991 Feb; 23(1 Pt 2):914-9.
    View in: PubMed
    Score: 0.005
  182. Use of FK 506 in pediatric patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):924-7.
    View in: PubMed
    Score: 0.005
  183. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
    View in: PubMed
    Score: 0.005
  184. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
    View in: PubMed
    Score: 0.005
  185. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet. 1990 Mar 17; 335(8690):674.
    View in: PubMed
    Score: 0.005
  186. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):106-9.
    View in: PubMed
    Score: 0.005
  187. FK 506 dosage in human organ transplantation. Transplant Proc. 1990 Feb; 22(1):23-4.
    View in: PubMed
    Score: 0.005
  188. Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
    View in: PubMed
    Score: 0.005
  189. The side effects of FK 506 in humans. Transplant Proc. 1990 Feb; 22(1):35-6.
    View in: PubMed
    Score: 0.005
  190. Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):41-3.
    View in: PubMed
    Score: 0.005
  191. Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc. 1990 Feb; 22(1):44-6.
    View in: PubMed
    Score: 0.005
  192. Assay of FK 506 in plasma. Transplant Proc. 1990 Feb; 22(1):50-1.
    View in: PubMed
    Score: 0.005
  193. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990 Feb; 22(1):57-9.
    View in: PubMed
    Score: 0.005
  194. Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):93-5.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.